TOG Review (RCOG Journal)

MRCOG Part 2

Core Surgical Skills

Perioperative management of women on oral anticoagulants and antiplatelet agents

Key Statistics

  • 10–15% — AF patients needing temporary interruption for elective surgery
  • ≥7 days — Recommended preop assessment before surgery
  • 5 days — Warfarin stopped preop, all bleeding risks

Don't-miss facts

  1. Warfarin: stop 5 days preop (all risk levels); bridge with treatment-dose LMWH only if high thrombotic risk (Box 1)

  2. Bridging LMWH restart delayed ≥48h after high bleeding-risk surgery; warfarin restart evening/next day if haemostasis adequate

  3. Apixaban/rivaroxaban/edoxaban share one stop schedule by CrCl; dabigatran stratified separately (higher renal clearance, 80%)

  4. Aspirin monotherapy – continue for gynae procedures; dual antiplatelet post-ACS/stent – postpone surgery ≥6 months if possible

  5. Emergency warfarin reversal: 5 mg IV phytomenadione (6–8h available) or 25–50 u/kg 4-factor PCC (cannot wait)

  6. Idarucizumab reverses dabigatran; no reversal agent for clopidogrel (effect lasts 7–9 days) — use tranexamic acid ± donor platelets

  7. Neuraxial block: aspirin/NSAIDs need not stop; ADP antagonists stopped 7 days prior (treat as high bleeding risk)

  8. Box 2 bleeding risk: no risk = smear/exam/swabs; minor = LLETZ, hysteroscopy, Pipelle, polypectomy, vulval/cervical biopsy; major = all day-case/inpatient surgery

Quick agent snapshot

Aspirin: continue Warfarin: stop 5d Apixaban/rivaroxaban/edoxaban: stop 24–72h by CrCl

Dabigatran: stop 24–96h by CrCl Clopidogrel: 7d if high risk

Abbreviation Key

  • DOAC — direct oral anticoagulant (previously novel oral anticoagulant)
  • ADP — adenosine diphosphate
  • NIC — net ingredient cost
  • INR — international normalised ratio
  • LLETZ — large loop excision of the transformation zone
  • LMWH — low-molecular-weight heparin
  • NSAID — nonsteroidal anti-inflammatory drug
  • VTE — venous thromboembolism
  • PCC — prothrombin complex concentrate
  • TIA — transient ischaemic attack

Source: Goh E et al. Perioperative management of women on oral anticoagulants and antiplatelet agents undergoing gynaecological procedures. The Obstetrician & Gynaecologist 2022;22:131–136. doi:10.1111/tog.12650

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free